No top menu
<!-- no script -->
|
|
UT, Esclapeus Biopharmaceuticals ink deal to develop molecule to fight obesity |
| By
Jacob Corkins |
|
Jun 26, 2008
|
|
Esclapeus Biopharmaceuticals LLC, founded by Dr. Khew-Voon Chin, UT associate professor of medicine and director of genomic medicine in the College of Medicine, recently entered into a licensing agreement with the University to develop a small molecule intervention for obesity.
According Stephen Snider, UT director of technology licensing and contracts, “If successful, this molecule would be utilized to reduce the growing obesity epidemic, which is one of the most serious public health risks in the United States.”
While spending more than 20 years in cancer research, Chin came across an unexpected result: He found a drug that regulates cholesterol levels, which could be applied to treatment of obesity.
After making this discovery more than three years ago, Chin shifted half of his research team’s focus from cancer to obesity in order to combat one of the nation’s fastest-growing problems
Chin named his company, Esclapeus, after the Greek god of medicine and health.
Chin and Esclapeus Biopharmaceuticals add their names to the other 12 spin-off companies that have been developed by UT faculty since 1998.
For more information on these companies, visit http://www.utoledo.edu/research/TechTransfer/spin_offs.html.
|
|
| |
|
|
|
|
|
|
|
|
|
|
